Source: Myeloma – Hematology Advisor
Researchers sought to confirm the safety and efficacy of idecabtagene vicleucel in a real-world population of patients with relapsed/refractory multiple myeloma.
Read More
by | Jan 31, 2023 | Myeloma News | 0 comments
Source: Myeloma – Hematology Advisor
Researchers sought to confirm the safety and efficacy of idecabtagene vicleucel in a real-world population of patients with relapsed/refractory multiple myeloma.
Read More